Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population

Arthritis and Rheumatism

Volumn 62, Issue 10, 2010, Pages 3093-3100

  Wipff, J ^a   Dieude P ^a   Guedj, M ^b   Ruiz, B ^a   Riemekasten, G ^c   Cracowski, J L ^d   Matucci Cerinic, M ^e   Melchers, I ^f   Humbert, M ^g   Hachulla, E ^h   Airo, P ⁱ   Diot, E ^j   Hunzelmann, N ^k   Caramaschi, P ^l   Sibilia, J ^m   Valentini, G ⁿ   Tiev, K ^o   Girerd, B ^g   Mouthon, L ^a   Riccieri, V ^p   Carpentier, P H ^d   Distler, J ^q   Amoura, Z ^r   Tarner, I ^s   Degano, B ^t   Avouac, J ^a   Meyer, O ^a   Kahan, A ^a   Boileau, C ^a,u   Allanore, Y ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h UNIV LILLE   (France)

ⁱ SPEDALI CIVILI   (Italy)

^j CHU BRETONNEAU   (France)

^k UNIVERSITY OF COLOGNE   (Germany)

^l UNIVERSITY OF VERONA   (Italy)

^m UNIVERSITÉ DE STRASBOURG   (France)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o HÔPITAL SAINT ANTOINE   (France)

^p SAPIENZA UNIVERSITY OF ROME   (Italy)

^q UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^r SORBONNE UNIVERSITÉ   (France)

^s JUSTUS LIEBIG UNIVERSITY   (Germany)

^t UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^u LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL KV1.5; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

ADULT; AGED; CASE-CONTROL STUDIES; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; KV1.5 POTASSIUM CHANNEL; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SCLERODERMA, SYSTEMIC;

EID: 77957663155     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27607     Document Type: Article

References (36)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
2. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-9. (Pubitemid 34267428)
3. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91. (Pubitemid 20100285)
4. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35-62S.
5. Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007;8:607-15. (Pubitemid 46547014)
6. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-50. (Pubitemid 44497786)
7. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
8. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808-14. (Pubitemid 351829381)
9. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65. (Pubitemid 351374421)
10. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, et al. Mutations of the TGF-β type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-32.
11. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 2007;292:C1837-53. (Pubitemid 47080568)
12. Dieude P, Guedj M, Wipff J, Ruiz B, Hachulla E, Diot E, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009;60:2472-9.
13. Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009;60:225-33.
14. Dieude P, Wipff J, Guedj M, Ruiz B, Melchers I, Hachulla E, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009;60:3447-54.
15. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008;47:1185-92.
16. Kirsten H, Blume M, Emmrich F, Hunzelmann N, Mierau R, Rzepka R, et al. No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene. J Rheumatol 2008;35:1817-9.
17. Avouac J, Airo P, Dieude P, Caramaschi P, Tiev K, Diot E, et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European caucasian patients. J Rheumatol 2010;37:608-14.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
19. Valentini G, Matucci Cerinic M. Disease-specific quality indicators, guidelines and outcome measures in scleroderma. Clin Exp Rheumatol 2007;25:159-62. (Pubitemid 350167902)
20. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
21. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-66.
22. Cracowski JL, Yaici A, Sitbon O, Reynaud-Gaubert M, Renversez JC, Pison C, et al. Biomarkers as prognostic factors in pulmonary arterial hypertension: rationale and study design. Rev Mal Respir 2004;21:1137-43. In French.
23. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010;181:851-61.
24. Guedj M, Della-Chiesa E, Picard F, Nuel G. Computing power in case-control association studies through the use of quadratic approximations: application to meta-statistics. Ann Hum Genet 2007;71:262-70. (Pubitemid 46656505)
25. Shah JS. Genetics of systemic sclerosis associated pulmonary arterial hypertension; recent progress and current concepts. Curr Rheumatol Rep 2009;11:89-96.
26. Allanore Y, Avouac J, Kahan A. Systemic sclerosis: an update in 2008. Joint Bone Spine 2008;75:650-5.
27. v1.5 potassium channel gene regulation by Sp1 transcription factor and oxidative stress. Am J Physiol Heart Circ Physiol 2007;293:H2719-25.
28. + channel activity and enhances survival in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001;281:C157-65.
29. Platoshyn O, Brevnova EE, Burg ED, Yu Y, Remillard CV, Yuan JX. Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 2006;290:C907-16.
30. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007;104:11418-23.
31. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc: implications for vascular treatment strategies. Rheumatology (Oxford) 2008;47 Suppl 5:v18-20.
32. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients. Ann Rheum Dis 2010;69:218-21.
33. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2 deficient mice. Circ Res 2006;98:818-27.
34. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005;112:553-62.
35. Yang Y, Li J, Lin X, Yang Y, Hong K, Wang L, et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet 2009;54:277-83.
36. + channel kv1.5. Circ Res 2009;104:1390-8.